SCHEMBL6746293

SCHEMBL6746293

CS(=O)(=O)c1c(F)cc(C2=CCC=C2c2cccc(Br)c2)cc1F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 5/20 0.38
CDK2 P24941 1/20 0.32
CASP1 P29466 1/20 0.32
AURKA O14965 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
IKBKB O14920 1/20 0.31
ALDH1A1 P00352 2/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA5A P35218 1/20 0.31
CA9 Q16790 1/20 0.31
MEN1 O00255 1/20 0.31
NPC1 O15118 1/20 0.31
CYP1A2 P05177 1/20 0.31
RAB9A P51151 1/20 0.31
KMT2A Q03164 1/20 0.31
MMP1 P03956 1/20 0.30
MMP2 P08253 1/20 0.30
MMP3 P08254 1/20 0.30
MMP7 P09237 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6750091 0.87 CASP1 (0.35) PTGS2CASP1
SCHEMBL6745120 0.87 ACLY (0.35) PTGS2CASP1ALDH1A1MEN1RAB9A
SCHEMBL6744935 0.87 PTGS2 (0.36) PTGS2CASP1CA2CA9
SCHEMBL6746349 0.86 PTGS2 (0.41) PTGS2CASP1
SCHEMBL6745114 0.85 SDHB (0.38) PTGS2CASP1CA1CA2GALR1
SCHEMBL6743237 0.84 PTGS2 (0.38) PTGS2CASP1MEN1RAB9AKMT2A
SCHEMBL6747363 0.82 PTGS2 (0.33) PTGS2CASP1
SCHEMBL6749791 0.82 PTGS2 (0.40) PTGS2IKBKBALDH1A1CA1CA2
SCHEMBL6743712 0.81 PTGS2 (0.44) PTGS2CYP1A2HPGD
SCHEMBL6750004 0.81 PTGS2 (0.46) PTGS2CASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6699884-B2 ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. PHARMACIA CORPORATION 2004-03-02 US claimed
US-6699884-B2 ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. PHARMACIA CORPORATION 2004-03-02 US disclosed